Cold-adapted, live attenuated influenza vaccine.
Cold-adapted, live attenuated influenza vaccine.
复制标题
DOI：
10.1586/14760584.3.2.131
复制
发表时间：
2004-04-01
影响因子：
6.2
通讯作者：
Glezen, W Paul
中科院分区：
文献类型：
--
作者：
Glezen, W Paul
最近获得许可的冷适应减毒流感疫苗（CAIV-T、FluMist、MedImmune Vaccines Inc.）有潜力加强对流行性流感的控制。鼻内疫苗已被证明安全有效。 CAIV-T 的监管限制和成本阻碍了该疫苗在第一年的推出。对病毒可能从疫苗接种者传播到免疫功能低下患者的不必要的担忧限制了医护人员的使用。 2003-2004年甲型H3N2流感的严重流行凸显了补充当前控制流感努力的必要性。据记录，已有超过 120 例儿童死亡，其中大多数以前都是健康的。在儿童中使用 CAIV-T 不仅可以降低严重疾病的风险，还可以抑制病毒在社区中的传播，并减少高危并发症和死亡患者的暴露。
The recently licensed cold-adapted, live attenuated influenza vaccine (CAIV-T, FluMist, MedImmune Vaccines Inc.) has the potential to enhance control of epidemic influenza. The intranasal vaccine has proven safety and efficacy. Regulatory constraints and cost of CAIV-T have hampered the introduction of the vaccine in the first year. Unwarranted concern about possible transmission of the virus from vaccine recipients to immunocompromised patients limited use in healthcare personnel. The intense influenza A(H3N2) epidemic of 2003-2004 has underscored the necessity of supplementing current efforts to control influenza. Over 120 deaths have been documented in children - the majority of which have been previously healthy. Use of CAIV-T in children will not only decrease the risk of serious disease, but also dampen the spread of the virus in the community and reduce exposure of patients who are at high risk of complications and death.